PolyActiva Appoints Jerry St. Peter as CEO and Secures $25M Series C Financing to Accelerate US Expansion and Clinical Advancement of PREZIA™ Technology Platform
CEO appointment and funding to support transformational US expansion, accelerate late-stage clinical development of lead asset, and strengthen R&D pipeline MELBOURNE, Australia & FORT WORTH, Texas–(BUSINESS WIRE)–PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug…